3-(4-methoxybenzamido)propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(4-methoxybenzamido)propanoic acid
• 英文别名: 3-[(4-methoxybenzoyl)amino]propanoic acid
• 化学式: C₁₁H₁₃NO₄
• mdl: MFCD00995793
• 分子量: 223.229
• InChiKey: WXKWDNRHJJLROS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-methoxybenzamido)propanoic acid 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 2.0h， 生成 1-(4-methoxybenzoyl)piperidine-2,4-dione
  参考文献：
  名称：

  抗菌3-酰基四酸和3-酰基哌啶-2,4-二酮的详细研究

  摘要：

  受到抗菌天然产物（例如链霉菌丝蛋白），3-酰基四酸和3-酰基哌啶-2,4-二酮的核心片段的启发，已通过直接与取代的羧酸进行酰化反应从核心杂环合成了一种策略，该策略允许随时使用结构上多样化的化合物库。这些系统的抗菌活性已经针对一系列革兰氏阳性和革兰氏阴性细菌而建立，并且大部分针对前者，在某些情况下非常有效。已获得与针对该文库一小部分的十一碳烯基焦磷酸合酶（UPPS）和/或RNA聚合酶（RNAP）的作用方式一致的数据。活性最高的化合物已显示出在UPPS和RNAP的链霉菌毒素和粘质激肽的已知结合位点上具有结合力。

  DOI：

  10.1002/cmdc.201402093
• 作为产物：
  描述：

  1-(4-甲氧基苯甲酰基)氮杂环丁烷-2-酮 在 P99 β-lactamase from Enterobacter cloacae 作用下， 以 various solvent(s) 为溶剂， 生成 3-(4-methoxybenzamido)propanoic acid
  参考文献：
  名称：

  Different Transition-State Structures for the Reactions of β-Lactams and Analogous β-Sultams with Serine β-Lactamases

  摘要：

  beta-Sultams are the sulfonyl analogues of beta-lactams, and N-acyl beta-sultams are novel inactivators of the class C beta-lactamase of Enterobacter cloacae P99. They sulfonylate the active site serine residue to form a sulfonate ester which subsequently undergoes C-O bond fission and formation of a dehydroalanine residue by elimination of the sulfonate anion as shown by electrospray ionization mass spectroscopy. The analogous N-acyl beta-lactams are substrates for beta-lactamase and undergo enzyme-catalyzed hydrolysis presumably by the normal acylation-deacylation process. The rates of acylation of the enzyme by the beta-lactams, measured by the second-order rate constant for hydrolysis, k(cat)/K-m, and those of sulfonylation by the beta-sultams, measured by the second-order rate constant for inactivation, k(i), both show a similar pH dependence to that exhibited by the beta-lactamase-catalyzed hydrolysis of beta-lactam antibiotics. Electron-withdrawing groups in the aryl residue of the leaving group of N-aroyl beta-lactams increase the rate of alkaline hydrolysis and give a Bronsted beta(Ig) of -0.55, indicative of a late transition state for rate-limiting formation of the tetrahedral intermediate. Interestingly, the corresponding Bronsted beta(Ig) for the beta-lactamase-catalyzed hydrolysis of the same substrates is -0.06, indicative of an earlier transition state for the enzyme-catalyzed reaction. By contrast, although the Bronsted beta(Ig) for the alkaline hydrolysis of N-aroyl beta-sultams is -0.73, similar to that for the beta-lactams, that for the sulfonylation of beta-lactamase by these compounds is -1.46, compatible with significant amide anion expulsion/S-N fission in the transition state. In this case, the enzyme reaction displays a later transition state compared with hydroxide-ion-catalyzed hydrolysis of the beta-sultam.

  DOI：

  10.1021/ja056124z

文献信息

• Visible Light-Mediated Decarboxylation Rearrangement Cascade of ω-Aryl-<i>N</i>-(acyloxy)phthalimides
  作者：Christian Faderl、Simon Budde、Georgiy Kachkovskyi、Daniel Rackl、Oliver Reiser

  DOI：10.1021/acs.joc.8b01538

  日期：2018.10.5

  A Smiles-type radical rearrangement induced by visible-light-mediated decarboxylation of ω-aryl-N-(acyloxy)phthalimides was developed, giving rise to pharmacologically important substance classes: phenylethylamine derivatives, dihydroisoquinolinones, and benzoazepinones were synthesized on the basis of readily available benzoic acids or benzaldehydes and β- or γ-amino acids. This methodology facilitates

  研制了由可见光介导的ω-芳基-N-（酰氧基）邻苯二甲酰亚胺的脱羧作用引起的Smiles型自由基重排，产生了重要的药理物质类别：苯乙胺衍生物，二氢异喹啉酮和苯并a庚酮可用的苯甲酸或苯甲醛以及β-或γ-氨基酸。该方法促进了对映纯的D-苯异丙胺和辣椒素类支气管扩张剂的前体的合成。
• WRINKLE-IMPROVING AGENT
  申请人：Shiseido Company, Limited

  公开号：EP1941861A1

  公开（公告）日：2008-07-09

  The invention provides a novel wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives, and salts thereof have a wrinkle-improving effect, whereby a wrinkle-improving agent containing as an active component one, two, or more types of compounds selected from the group composed of these specific β-alanine derivatives and the salts thereof was developed.

  该发明提供了一种新型的改善皱纹的剂，具有改善皱纹的效果，即使应用于皮肤也不会带来安全或疼痛问题，并且包含一种非常安全的物质作为活性成分。发现N-苯甲酰-β-丙氨酸、其他特定的β-丙氨酸衍生物及其盐具有改善皱纹的效果，因此开发了一种改善皱纹的剂，其活性成分包含从这些特定的β-丙氨酸衍生物及其盐组成的群体中选择的一种、两种或更多种化合物。
• Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition
  作者：Na Li、Jinfeng Ou、Na Bao、Cheng Chen、Zhixian Shi、Li Chen、Jianbo Sun

  DOI：10.1016/j.bioorg.2020.104208

  日期：2020.11

  hydroxyl group at C-5 of PL might interact with STAT3 in the form of hydrogen bonds, which is conducive to the binding of this kind structures with STAT3. Among the target compounds, 7a displayed the most potent inhibition against cancer cells and weaker cytotoxicity on normal cells than PL. The western bolting analysis showed that 7a could suppress the phosphorylation of STAT3 as well as the downstream genes

  基于信号转导和转录激活因子3（STAT3）的结构，设计，合成了一系列具有STAT3抑制潜能的plumbagin（PL）衍生的1,4-萘醌，并在体外对几种人类癌细胞系进行了生物学评估。（MDA-MB-231，HepG2和A549细胞）和三个正常细胞。结构-活性关系（SAR）和分子对接结果表明，PL C-5处的羟基可能以氢键形式与STAT3相互作用，这有利于这种结构与STAT3的结合。在目标化合物中，与PL相比，7a对癌细胞的抑制作用最强，对正常细胞的细胞毒性较弱。西方螺栓分析显示7a可以抑制STAT3及其下游基因的磷酸化，而不影响其上游酪氨酸激酶（Src和JAK2）水平和p-STAT1表达。此外，分子对接表明7a与STAT3的结合比PL更紧密，并且可以显着诱导体外癌细胞的凋亡。所有这些结果可为发现有效的STAT3抑制剂提供参考。
• MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR
  申请人：West Michael Leo

  公开号：US20100184607A1

  公开（公告）日：2010-07-22

  A monosaccharide compound of formula I as shown in the specification. Processes for the preparation of the compound of formula I and methods of screening for antibacterial or antibiotic compounds involving the compound of formula I.

  一种单糖化合物，其化学式I如规范中所示。制备化学式I化合物的方法以及涉及化学式I化合物的抗菌或抗生素化合物筛选方法。
• Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin
  申请人：Kaminuma Mikiko

  公开号：US20120232111A1

  公开（公告）日：2012-09-13

  The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin—inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and further provides an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent comprises one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof. The external composition for skin comprises the one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent.

  本发明提供了一种角化过度抑制剂、毛孔收缩剂或粗糙肌肤预防/改善剂，具有诸如角化过度抑制、毛孔收缩或粗糙肌肤抑制/减轻等功能，不会引起感觉刺激等安全问题，非常安全，还提供了一种外用皮肤组成物，其中添加了具有上述功能的化合物。该角化过度抑制剂、毛孔收缩剂或粗糙肌肤预防/改善剂包括从β-丙氨酸衍生物和其盐的群组中选择的一种或多种化合物。该外用皮肤组成物包括上述β-丙氨酸衍生物和其盐中的一种或多种作为上述角化过度抑制剂、毛孔收缩剂或粗糙肌肤预防/改善剂。